|
|
|
|
||
Re: IMGN aficionadosLatest 10Q shows that both Indatuximab Ravtansine and TAK164 out licenses are "pending termination" (see page 7): Again, multiple myeloma seems to be a competitive space now with CD38 mabs leading the charge. TAK164 seems to be using a linker / payload that's less suitable for solid tumors than a maytansinoid based one with more bystander killing activity. (One wonders how much the bystander killing activity of the linker / payload synergizes with the effect of Bev. in solid tumors...) |
return to message board, top of board |